Clinical Trials Logo

Crimean-Congo Hemorrhagic Fever clinical trials

View clinical trials related to Crimean-Congo Hemorrhagic Fever.

Filter by:
  • None
  • Page 1

NCT ID: NCT03020771 Completed - Clinical trials for Crimean-Congo Hemorrhagic Fever

Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This study covers the first trial of the Crimean-Congo Hemorrhagic fever virus (CKKA) vaccine on humans (healthy volunteers), which has been developed in Turkey and has completed preclinical toxicology studies to be performed on experimental animals. Also, this study is a Phase I, randomized, double-blind, national, single-center, placebo-controlled study that is designed to evaluate the safety and efficacy of the CKKA vaccine. A total of 60 (12 + 48) healthy male and/or female volunteers will be participating in this study, and the study is planned to last approximately one year.

NCT ID: NCT00992693 Withdrawn - Lassa Fever Clinical Trials

Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of the safety and efficacy of Intravenous (IV) Ribavirin in treating patients presenting with a probable or suspected case of viral hemorrhagic fever (either Crimean Congo or Lassa Fever) at a military medical treatment hospital. All patients will be treated with a 10 day course of IV Ribavirin if they meet all the inclusion and none of the exclusion criteria.